參考文獻 |
Acunzo M, Romano G, Palmieri D, Lagana A, Garofalo M, Balatti V, Drusco A, Chiariello M, Nana-Sinkam P, Croce CM. 2013. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America 110: 8573-8578.
Alberg AJ, Brock MV, Samet JM. 2005. Epidemiology of lung cancer: looking to the future. J Clin Oncol 23: 3175-3185.
Alexandrova AY, Kopnin PB, Vasiliev JM, Kopnin BP. 2006. ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res 312: 2066-2073.
Anwar A, Keating AK, Joung D, Sather S, Kim GK, Sawczyn KK, Brandao L, Henson PM, Graham DK. 2009. Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. J Leukoc Biol 86: 73-79.
Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG. 1997. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272: 217-221.
Bae YS, Sung JY, Kim OS, Kim YJ, Hur KC, Kazlauskas A, Rhee SG. 2000. Platelet-derived growth factor-induced H(2)O(2) production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 275: 10527-10531.
Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR. 2004. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059.
Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
Bellosta P, Costa M, Lin DA, Basilico C. 1995. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Molecular and cellular biology 15: 614-625.
Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al. 2010. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. The American journal of pathology 177: 415-423.
Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al. 2007. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current biology : CB 17: 1298-1307.
Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Gronbaek K, Federspiel B, Lund AH, Friis-Hansen L. 2011. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Molecular cancer 10: 29.
Bouchie A. 2013. First microRNA mimic enters clinic. Nature biotechnology 31: 577.
Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK. 2014. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia 28: 451-455.
Brognard J, Clark AS, Ni Y, Dennis PA. 2001. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997.
Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O′Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, et al. 2006. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Molecular cancer 5: 70.
Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nature reviews Cancer 6: 857-866.
Cavigelli M, Dolfi F, Claret FX, Karin M. 1995. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. The EMBO journal 14: 5957-5964.
Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular cell 26: 745-752.
Chen H, Lin YW, Mao YQ, Wu J, Liu YF, Zheng XY, Xie LP. 2012. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer letters 320: 40-47.
Chen QY, Xu LQ, Jiao DM, Yao QH, Wang YY, Hu HZ, Wu YQ, Song J, Yan J, Wu LJ. 2011. Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs. International journal of molecular medicine 28: 769-776.
Chin YR, Toker A. 2009. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 21: 470-476.
Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al. 2010. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer research 70: 8822-8831.
Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH. 2010. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell death and differentiation 17: 236-245.
Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. 2003. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 22: 533-540.
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 16: 1119-1128.
Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG. 1995. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797.
Davalos AR, Coppe JP, Campisi J, Desprez PY. 2010. Senescent cells as a source of inflammatory factors for tumor progression. Cancer metastasis reviews 29: 273-283.
Delhalle S, Deregowski V, Benoit V, Merville MP, Bours V. 2002. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 21: 3917-3924.
Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. 2001. Gas6 anti-apoptotic signaling requires NF-kappa B activation. The Journal of biological chemistry 276: 31738-31744.
Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T, et al. 2007. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer science 98: 1845-1852.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
Esme H, Cemek M, Sezer M, Saglam H, Demir A, Melek H, Unlu M. 2008. High levels of oxidative stress in patients with advanced lung cancer. Respirology 13: 112-116.
Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nature reviews Cancer 6: 259-269.
Fang Y, Xue JL, Shen Q, Chen J, Tian L. 2012. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 55: 1852-1862.
Farooqui R, Zhu S, Fenteany G. 2006. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. Exp Cell Res 312: 1514-1525.
Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, Galeotti T. 2006. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 25: 3689-3698.
Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET. 1996. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Molecular and cellular biology 16: 135-145.
Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F. 2005. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105: 1970-1976.
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al. 2012. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature medicine 18: 74-82.
Gastonguay A, Berg T, Hauser AD, Schuld N, Lorimer E, Williams CL. 2012. The role of Rac1 in the regulation of NF-kappaB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer biology & therapy 13: 647-656.
Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. 1999. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Molecular and cellular biology 19: 1171-1181.
Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, et al. 2015. Antitumour activity of an inhibitor of miR-34a in liver cancer with beta-catenin-mutations. Gut.
Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP, Srivastava AN. 2010. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology 15: 349-356.
Hafizi S, Dahlback B. 2006. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine & growth factor reviews 17: 295-304.
Hafizi S, Ibraimi F, Dahlback B. 2005. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J 19: 971-973.
Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. 2004. Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 287: H1207-1213.
Heiring C, Dahlback B, Muller YA. 2004. Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family. The Journal of biological chemistry 279: 6952-6958.
Hempel N, Ye H, Abessi B, Mian B, Melendez JA. 2009. Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic Biol Med 46: 42-50.
Hermeking H. 2010. The miR-34 family in cancer and apoptosis. Cell death and differentiation 17: 193-199.
Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer research 70: 1544-1554.
Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. 2008. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer letters 268: 314-324.
Huang JS, Cho CY, Hong CC, Yan MD, Hsieh MC, Lay JD, Lai GM, Cheng AL, Chuang SE. 2013. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free radical biology & medicine 65: 1246-1256.
Huang Q, Sheibani N. 2008. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 295: C1647-1657.
Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, et al. 2012. Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS One 7: e52397.
Inui M, Martello G, Piccolo S. 2010. MicroRNA control of signal transduction. Nature reviews Molecular cell biology 11: 252-263.
Inumaru J, Nagano O, Takahashi E, Ishimoto T, Nakamura S, Suzuki Y, Niwa S, Umezawa K, Tanihara H, Saya H. 2009. Molecular mechanisms regulating dissociation of cell-cell junction of epithelial cells by oxidative stress. Genes Cells 14: 703-716.
Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human MicroRNA targets. PLoS Biol 2: e363.
Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H. 2011. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 10: M111 010462.
Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et al. 2008. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer research 68: 3566-3572.
Kim D, Song J, Kim S, Park HM, Chun CH, Sonn J, Jin EJ. 2012. MicroRNA-34a modulates cytoskeletal dynamics through regulating RhoA/Rac1 cross-talk in chondroblasts. The Journal of biological chemistry 287: 12501-12509.
Komatsu D, Kato M, Nakayama J, Miyagawa S, Kamata T. 2008. NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression. Oncogene 27: 4724-4732.
Konishi A, Aizawa T, Mohan A, Korshunov VA, Berk BC. 2004. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. J Biol Chem 279: 28766-28770.
Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A. 2009. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8: 618-626.
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. 2008. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785.
Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, et al. 2007. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer research 67: 3878-3887.
Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y, Giaccone G. 2011. MicroRNA expression and clinical outcome of small cell lung cancer. PloS one 6: e21300.
Lee WP, Wen Y, Varnum B, Hung MC. 2002. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21: 329-336.
Lee YS, Dutta A. 2009. MicroRNAs in cancer. Annual review of pathology 4: 199-227.
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115: 787-798.
Li J, Wang K, Chen X, Meng H, Song M, Wang Y, Xu X, Bai Y. 2012. Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC molecular biology 13: 4.
Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. 2006. Small dsRNAs induce transcriptional activation in human cells. Proceedings of the National Academy of Sciences of the United States of America 103: 17337-17342.
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. 2009a. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer letters 275: 44-53.
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al. 2008. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. International journal of cancer Journal international du cancer 123: 1616-1622.
Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al. 2009b. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer research 69: 7569-7576.
Liang Y, McDonnell S, Clynes M. 2002. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets 2: 257-277.
Linger RM, Keating AK, Earp HS, Graham DK. 2008. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83.
Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. 2009. Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL. Cancer Research 69: 6871-6878.
Lize M, Klimke A, Dobbelstein M. 2011. MicroRNA-449 in cell fate determination. Cell Cycle 10: 2874-2882.
Lize M, Pilarski S, Dobbelstein M. 2010. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell death and differentiation 17: 452-458.
Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. 2008. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
Luo W, Huang B, Li Z, Li H, Sun L, Zhang Q, Qiu X, Wang E. 2013. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PloS one 8: e64759.
Ma Y, Qin H, Cui Y. 2013. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochemical and biophysical research communications 441: 958-963.
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. 2011. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130: 663-679.
Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. 2005. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 65: 6789-6800.
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. 2002. Expression profile of tyrosine kinases in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 8: 361-367.
Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. 2013. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Science signaling 6: ra66.
Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM, Giordano S. 2008. MicroRNAs impair MET-mediated invasive growth. Cancer research 68: 10128-10136.
Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. 2011. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30: 2888-2899.
Mudduluru G, Vajkoczy P, Allgayer H. 2010. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Molecular cancer research : MCR 8: 159-169.
Nielsen-Preiss SM, Allen MP, Xu M, Linseman DA, Pawlowski JE, Bouchard RJ, Varnum BC, Heidenreich KA, Wierman ME. 2007. Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinase and ras stimulation of rac activity in immortalized gonadotropin-releasing hormone neuronal cells. Endocrinology 148: 2806-2814.
Nishikawa M. 2008. Reactive oxygen species in tumor metastasis. Cancer Lett 266: 53-59.
Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R. 2009. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724.
Novo E, Parola M. 2012. The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis & tissue repair 5: S4.
O′Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R, 3rd, Le Beau MM, Earp HS, Liu ET. 1991. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Molecular and cellular biology 11: 5016-5031.
Onishi K, Higuchi M, Asakura T, Masuyama N, Gotoh Y. 2007. The PI3K-Akt pathway promotes microtubule stabilization in migrating fibroblasts. Genes Cells 12: 535-546.
Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M. 2012. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PloS one 7: e47663.
Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T. 2000. A redox signaling mechanism for density-dependent inhibition of cell growth. J Biol Chem 275: 38891-38899.
Park SJ, Kim YT, Jeon YJ. 2012. Antioxidant dieckol downregulates the Rac1/ROS signaling pathway and inhibits Wiskott-Aldrich syndrome protein (WASP)-family verprolin-homologous protein 2 (WAVE2)-mediated invasive migration of B16 mouse melanoma cells. Mol Cells 33: 363-369.
Pelicano H, Carney D, Huang P. 2004. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110.
Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. 2008. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proceedings of the National Academy of Sciences of the United States of America 105: 1608-1613.
Qian Y, Zhong X, Flynn DC, Zheng JZ, Qiao M, Wu C, Dedhar S, Shi X, Jiang BH. 2005. ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene 24: 3154-3165.
Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, et al. 2005. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127.
Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular cell 26: 731-743.
Reddy SD, Ohshiro K, Rayala SK, Kumar R. 2008. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer research 68: 8195-8200.
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, et al. 2014. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer research 74: 253-262.
Ribeiro J, Marinho-Dias J, Monteiro P, Loureiro J, Baldaque I, Medeiros R, Sousa H. 2015. miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development. BioMed research international 2015: 304584.
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. 2007. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. 1999. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13: 1352-1358.
Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. 2005. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44.
Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E. 2006. Structural basis for Gas6-Axl signalling. EMBO J 25: 80-87.
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. 2005. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064.
Srivastava AN, Gupta A, Srivastava S, Natu SM, Mittal B, Negi MP, Prasad R. 2010. Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients. Asian Pac J Cancer Prev 11: 465-471.
Stahlhut C, Slack FJ. 2015. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle 14: 2171-2180.
Storz P. 2005. Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896.
Sun D, Xu D, Zhang B. 2006. Rac signaling in tumorigenesis and as target for anticancer drug development. Drug Resist Updat 9: 274-287.
Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. 2008. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 27: 4044-4055.
Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proceedings of the National Academy of Sciences of the United States of America 104: 15472-15477.
Tobar N, Caceres M, Santibanez JF, Smith PC, Martinez J. 2008. RAC1 activity and intracellular ROS modulate the migratory potential of MCF-7 cells through a NADPH oxidase and NFkappaB-dependent mechanism. Cancer Lett 267: 125-132.
Tochhawng L, Deng S, Pervaiz S, Yap CT. 2012. Redox regulation of cancer cell migration and invasion. Mitochondrion.
Toyokuni S, Okamoto K, Yodoi J, Hiai H. 1995. Persistent oxidative stress in cancer. FEBS Lett 358: 1-3.
Tsai LH, Chen PM, Cheng YW, Chen CY, Sheu GT, Wu TC, Lee H. 2014. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas. Oncogene 33: 3851-3860.
Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA. 2006. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306-314.
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, et al. 2006. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 103: 5799-5804.
Valverde P. 2005. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun 333: 180-185.
Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H. 2011. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Archiv : an international journal of pathology 458: 313-322.
Wang MJ, Lin S. 2009. A region within the 5′-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. The Journal of biological chemistry 284: 36500-36510.
Wang X, McCullough KD, Franke TF, Holbrook NJ. 2000. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem 275: 14624-14631.
Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H. 2014. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell death & disease 5: e1227.
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. 2009. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. The Journal of biological chemistry 284: 5731-5741.
Weinberg F, Chandel NS. 2009. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 66: 3663-3673.
Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788-8793.
Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. 1995. Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407.
Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. 2001. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37: 2264-2274.
Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. 2002. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22: 1071-1078.
Wu WS. 2006. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25: 695-705.
Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. 2014. AXL kinase as a novel target for cancer therapy. Oncotarget 5: 9546-9563.
Wu YM, Robinson DR, Kung HJ. 2004. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer research 64: 7311-7320.
Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. 2007. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67: 10823-10830.
Yamakuchi M, Ferlito M, Lowenstein CJ. 2008. miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences of the United States of America 105: 13421-13426.
Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, Lu F, Tu L, Qu J. 2009. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Investigative ophthalmology & visual science 50: 1559-1565.
Yanagita M, Arai H, Nakano T, Ohashi K, Mizuno K, Fukatsu A, Doi T, Kita T. 2001. Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. The Journal of biological chemistry 276: 42364-42369.
Younger ST, Corey DR. 2011. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic acids research 39: 5682-5691.
Zhang JY, Zhang D, Wang EH. 2011. Overexpression of small GTPases directly correlates with expression of delta-catenin and their coexpression predicts a poor clinical outcome in nonsmall cell lung cancer. Mol Carcinog.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. 2012. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature genetics 44: 852-860.
Zhao J, Kelnar K, Bader AG. 2014. In-depth analysis shows synergy between erlotinib and miR-34a. PloS one 9: e89105.
Zieba M, Suwalski M, Kwiatkowska S, Piasecka G, Grzelewska-Rzymowska I, Stolarek R, Nowak D. 2000. Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir Med 94: 800-805. |